Melinta Therapeutics Inc. buy marge
Summary
This prediction ended on 02.05.17 with a price of €90.77. Massive losses of -48.06% were the result for the BUY prediction by marge. marge has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Melinta Therapeutics Inc. | - | - | - | - |
iShares Core DAX® | 4.094% | 3.543% | 17.404% | 20.326% |
iShares Nasdaq 100 | 1.424% | 0.512% | 39.212% | 55.365% |
iShares Nikkei 225® | -1.572% | -4.633% | 15.731% | 2.146% |
iShares S&P 500 | 1.822% | 0.963% | 30.396% | 45.950% |
Comments by marge for this prediction
In the thread Melinta Therapeutics Inc. diskutieren
marge stimmt dem augenblicklichen Sentiment von 'Sell' nicht zu
Importantly, the FDA did not order the removal of telithromycin from the
market after these adverse events - it merely restricted it's approved
uses because the risk/benefit profile no longer justified all of the
initially approved uses. Critically, it remains approved for CABP of
mild to moderate severity, which is promising for the outlook of
solithromycin approval for the same indication. Also, solithromycin has a
big edge due to its superior performance against resistant bacteria. I
don't think the FDA can afford not to approve it, given the growing
crisis in antibacterial resistance, and the dwindling treatment options
out there.
Stopped prediction by marge for Melinta Therapeutics Inc.
Melinta Therapeutics Inc.
23.07.15
18.07.16
18.07.16
Melinta Therapeutics Inc.
21.06.15
21.07.15
21.07.15